Transitioning To Bona Fide Pharmacy
Following the development, Deutsche Bank said in a note released on Tuesday that the company has taken a giant leap in its transformation from a dollar store to a bona fide pharmacy. The firm noted that the company is poised to become a long-term viable competitor in the space with a more national footprint.
Risk/Reward Balanced
While viewing the deal value as favorable, analyst Paul Trussell said the markets have now folded the value into the current stock price. The analyst views the risk/reward as balanced, as it expects material projected accretion and cash flow as well as the benefits of greater scale and the TSA versus integration and execution challenges, plus lingering industry issues in both pharmacy and the front-end.
Remaining On The Sidelines
Deutsche Bank also raised questions regarding procurement and merchandising, bannering over the longer term, the geographic mix of the new footprint and potential DC needs, capital allocation and whether the new management team can effectively operate 1,500 stores despite struggles with the current base. The firm said it would remain on the sidelines, awaiting clarity on these issues.
Raising Estimate, Price Target
Factoring in the new store additions at the end of the second quarter, the firm raised its 2017 earnings per share estimate to $1 from -$0.12. The firm also raised its price target to $23 from $8 following Tuesday's run up. The firm has a Hold rating on Fred's.
In pre-market trading, shares of Fred's were pulling back 0.99 percent to $20.19.
Image Credit: By Michael Rivera (Own work) [CC BY-SA 3.0], via Wikimedia Commons
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.